评估 COVID-19 大流行期间晚期非小细胞肺癌中扩展剂量的 pembrolizumab。
An assessment of extended pembrolizumab dosing in advanced non-small-cell lung cancer in the COVID-19 pandemic.
机构信息
Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, M5G 1X6, Canada.
Department of Oncology, University of Toronto, Toronto, ON, M5G 1X6, Canada.
出版信息
Immunotherapy. 2023 Aug;15(12):921-932. doi: 10.2217/imt-2022-0257. Epub 2023 Jul 11.
There are limited clinical data comparing extended dosing (ED) versus standard dosing (SD) of pembrolizumab for metastatic non-small-cell lung cancer. This retrospective study included patients with metastatic non-small-cell lung cancer and PD-L1 tumor proportion score ≥50% treated with one or more cycles of single-agent pembrolizumab with SD or ED from January 2018 to December 2020. A higher proportion of patients were alive in the ED group (vs SD) at 6 months (94 vs 51%), 12 months (94 vs 33%) and data cutoff (94 vs 26%) (p < 0.001 for all). The rate (44 vs 32%; p = 0.407) and severity of grade ≥3 immune-related adverse events were similar (50 vs 52%); however, ED patients more frequently discontinued treatment due to toxicity (45 vs 15%; p < 0.001). A greater proportion of ED patients were alive at data cutoff, and the rate and severity of immune-related adverse events were similar between groups.
针对转移性非小细胞肺癌，与标准剂量（SD）相比，延长给药（ED）派姆单抗的临床数据有限。这项回顾性研究纳入了 2018 年 1 月至 2020 年 12 月期间接受过单药派姆单抗治疗且 PD-L1 肿瘤比例评分≥50%的转移性非小细胞肺癌患者，这些患者接受了 1 个或多个周期的 SD 或 ED 治疗。在 6 个月（94% vs 51%，p<0.001）、12 个月（94% vs 33%，p<0.001）和数据截止时（94% vs 26%，p<0.001），ED 组的存活患者比例更高。ED 组和 SD 组≥3 级免疫相关不良事件的发生率（44% vs 32%；p=0.407）和严重程度相似（50% vs 52%）；然而，由于毒性，ED 组患者更频繁地停止治疗（45% vs 15%；p<0.001）。ED 组在数据截止时存活患者的比例更高，且两组之间免疫相关不良事件的发生率和严重程度相似。
Zotero 插件